Gregory Lucier Sells 82,200 Shares of DENTSPLY SIRONA (NASDAQ:XRAY) Stock

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Director Gregory Lucier sold 82,200 shares of the company’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $11.14, for a total transaction of $915,708.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

DENTSPLY SIRONA Price Performance

Shares of NASDAQ:XRAY traded up $0.54 during trading on Wednesday, reaching $11.65. 5,101,155 shares of the company’s stock traded hands, compared to its average volume of 3,138,867. DENTSPLY SIRONA Inc. has a fifty-two week low of $9.85 and a fifty-two week high of $20.59. The company has a quick ratio of 0.99, a current ratio of 1.47 and a debt-to-equity ratio of 1.36. The firm has a market cap of $2.32 billion, a PE ratio of -2.64, a P/E/G ratio of 0.81 and a beta of 1.01. The company has a 50-day simple moving average of $11.84 and a 200-day simple moving average of $13.83.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $0.37 earnings per share for the quarter, missing analysts’ consensus estimates of $0.45 by ($0.08). The business had revenue of $904.00 million during the quarter, compared to analyst estimates of $900.33 million. DENTSPLY SIRONA had a positive return on equity of 17.10% and a negative net margin of 24.34%.The business’s revenue for the quarter was down 4.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.50 EPS. DENTSPLY SIRONA has set its FY 2025 guidance at 1.600-1.600 EPS. As a group, analysts predict that DENTSPLY SIRONA Inc. will post 1.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on XRAY shares. Evercore ISI decreased their target price on DENTSPLY SIRONA from $17.00 to $13.00 and set an “in-line” rating on the stock in a research report on Wednesday, October 8th. Wall Street Zen downgraded shares of DENTSPLY SIRONA from a “buy” rating to a “hold” rating in a report on Saturday, October 18th. UBS Group dropped their target price on shares of DENTSPLY SIRONA from $24.00 to $23.00 and set a “buy” rating on the stock in a research report on Tuesday, October 28th. Weiss Ratings restated a “sell (d-)” rating on shares of DENTSPLY SIRONA in a research report on Wednesday, October 8th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of DENTSPLY SIRONA in a report on Friday, September 26th. Two investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Reduce” and an average price target of $15.77.

Hedge Funds Weigh In On DENTSPLY SIRONA

Hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its position in DENTSPLY SIRONA by 4.1% during the third quarter. Vanguard Group Inc. now owns 22,006,576 shares of the medical instruments supplier’s stock worth $279,263,000 after acquiring an additional 869,566 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in DENTSPLY SIRONA by 11.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 13,961,759 shares of the medical instruments supplier’s stock valued at $208,590,000 after acquiring an additional 1,412,517 shares during the last quarter. AQR Capital Management LLC lifted its stake in DENTSPLY SIRONA by 109.8% in the 2nd quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock worth $211,470,000 after purchasing an additional 6,970,086 shares in the last quarter. Fuller & Thaler Asset Management Inc. boosted its holdings in shares of DENTSPLY SIRONA by 4.7% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 12,077,949 shares of the medical instruments supplier’s stock worth $180,445,000 after purchasing an additional 538,531 shares during the last quarter. Finally, Lazard Asset Management LLC boosted its holdings in shares of DENTSPLY SIRONA by 0.9% during the 3rd quarter. Lazard Asset Management LLC now owns 10,200,525 shares of the medical instruments supplier’s stock worth $129,445,000 after purchasing an additional 92,868 shares during the last quarter. 95.70% of the stock is owned by hedge funds and other institutional investors.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.